ExaWizards Inc.
Notice on the Initiation of Preliminary Comprehensive Evaluation Consultation for ExaMD
Announces the PMDA preliminary comprehensive evaluation consultation for ExaMD’s cognitive function AI diagnostic support app. Advancing fixed data for clinical trials and statistical analysis, aiming for manufacturing and marketing approval and early market introduction within FY2026. The impact on consolidated results for FY2027 is expected to be minor, with further assessment planned.
Key Figures
- Progress of fixed data and statistical analysis for clinical trials (observation completed, data locked, statistical analysis)
- Aiming to obtain manufacturing and marketing approval and early market launch within FY2026
- Impact on FY2027 full-year consolidated results minor, no revisions
AI要約
Section Heading
This notice informs that ExaMD, the subsidiary, is developing a cognitive function AI diagnostic support SaMD, and that the PMDA has accepted and initiated the Preliminary Comprehensive Evaluation Consultation. Trials will continue data locking and statistical analysis, leveraging the priority review designation to accelerate preparations for approval submission. It outlines an outlook toward obtaining manufacturing and marketing approval and starting sales within FY2026, with the impact on FY2027 performance deemed minor at present.
Second Section Heading
Looking ahead, by parallel with the start of the preliminary comprehensive evaluation consultation, evaluations of clinical and non-clinical data, QMS, and reliability will be organized with the PMDA in advance to streamline reviews and shorten review timelines. Data locking will promptly advance statistical analysis to maximize the benefits of the priority review designation. Financial impact is currently limited, and additional information will be disclosed as it becomes available.
ExaWizards, Inc.
Company overview · Stock price · Financial data · All IR
